



Avexa Limited  
ABN 53 108 150 750  
576 Swan Street Richmond  
Victoria Australia 3121

Telephone 61 3 9208 4300  
Facsimile 61 3 9208 4004  
Website [www.avexa.com.au](http://www.avexa.com.au)

## ASX Release

21 February 2008

### AVEXA LIMITED BROADCAST

**AVEXA LIMITED (AVX)** provides the opportunity to listen to an audio broadcast with **Dr Julian Chick, CEO** in a presentation titled "**AVX - Avexa Half Year Report 31 December 2007 - Dr Julian Chick, CEO**".

*To listen, simply click on the link below:*

<http://www.brr.com.au/event/41168>

The presentation details are as follows:

- **AVX - Avexa Half Year Report 31 December 2007 - Dr Julian Chick, CEO**
- **Presented by Dr Julian Chick, CEO**
- **Thu, 21 Feb 2008 02:30PM AEST**

**Boardroomradio offers many free services, such as:**

- [Boardroomradio Alerts](#)
- Easy access to archived presentations on demand
- Podcast subscription with daily updates

Visit <http://www.brr.com.au> for more

#### **For more information:**

Dr. Julian Chick  
Chief Executive Officer  
+61 3 9208 4300

Mr Rod North  
Bourse Communications  
+ 61 (03) 9510-8309

[www.avexa.com.au](http://www.avexa.com.au)

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including its HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC), an anti-HIV drug which has successfully completed the 24 week dosing of its Phase 2b trial and continues to progress towards Phase 3 trials. Avexa has entered into a collaboration with TargetDrug in China to identify new CCR5 inhibitors for the treatment of HIV.